<DOC>
	<DOCNO>NCT01199432</DOCNO>
	<brief_summary>This phase IV , prospective , single-center , open-label , randomize , control study . Eligible patient randomly assign three group . The investigator propose evaluate compare efficacy safety different neoadjuvant chemotherapy woman primary breast cancer .</brief_summary>
	<brief_title>Comparative Efficiency Three Regimen , CEFci , CEF EC Neoadjuvant Chemotherapy Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patient , age ≦ 65 year old Histologically cytologically confirm primary breast cancer core biopsy Disease stage appropriate neoadjuvant chemotherapy ( T2～T3，N0～2，M0 ) No previous treatment breast cancer No history malignancies No currently uncontrolled diseased ( e.g. , ongoing cardiac dysrhythmias , unstable diabetes ) active infection No history malignancies No currently uncontrolled diseased active infection Not pregnant breast feeding , appropriate birth control childbearing potential Adequate cardiovascular function reserve without myocardial infarction within past six month Adequate hematologic function : 1 . Absolute neutrophil count ( ANC ) ≥ 1500/mm3 2 . Platelets ≥ 100,000/ mm3 3 . Hemoglobin ≥ 10 g/dL Adequate hepatic renal function : 1 . Serum bilirubin ≤ 1.5×UNL 2 . Alkaline phosphatase alanine aminotransferase ( ALT ) ≤ 2.5 x ULN . 3 . Serum creatinine ≤ 1.7 mg/dl Knowledge investigational nature study Ability give inform consent Ability willingness comply study procedure Known suspect distant metastasis Concurrent malignancy history malignancy Uncontrolled disease active infection Hepatic renal dysfunction detail Geographical , social , psychological problem would compromise study compliance Known suspect hypersensitivity cyclophosphamide , epirubicin fluorouracil</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Primary Breast Cancer</keyword>
</DOC>